Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
But Humira remains the one to beat.
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.
For $4bn up front, Takeda buys into the Tyk2 mechanism – and Nimbus and its backers get a huge pay day.